Abstract
Cefzon® (cefdinir, CFDN, Fujisawa Pharmaceutical Co., Ltd.) is an oral cephem antibiotic which was marketed in 1991. It has been confirmed that the clinical efficacy of cefdinir in the treatment of respiratory tract infections was 85.0% or more and the safety of cefdinir was high in the field of pediatrics. In this study the clinical efficacy of cefdinir in cases of acute otitis media was investigated in 47 pediatric patients aged 3 months to 11 years and 9 months. The clinical efficacy rate was 83.0% and the bacteriological eradication rate was 79.2% in all of these patients. The main pathogens isolated from these patients were Haemophilus influenzae (41.1%), Streptococcus pneumoniae (30.4%) and coagulase negative staphylococci (CNS) (12.5%). The eradication rates of thesepathogens were 82.6% (19/23 patients) for H. influenzae and 78.6% (11/14 patients) for S. pneumoniae. The efficacy rate of cefdinir in monomicrobial infections was 89.7% (26/29 patients) but the efficacy rate in polymicrobial infections was 64.3% (9/14 patients).As adverse reactions, diarrhea was observed in 3 patients (6%) but disappeared in 1 patient 3 days after discontinuation of the drug and administration was continued in the remaining 2 patients.The superior efficacy of cefdinir in treatment of acute otitis media was attributed to the high concentrations of cefdinir which exceeded MICs against H. influenzae or S. pneumoniae in tympanic mucosa.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
